Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI306 in Chinese Patients With Hypercholesterolemia
CTR20190220Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tafolecimab in hypercholesterolemia, sponsored by Innovent Biologics. Started Feb 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20190220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190220.